Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests in HCV Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies Either Alone or in Combination With Ribavirin

NCT02293941 is registered in ClinicalTrials.gov with TaiwanJ Pharmaceuticals Co., Ltd as lead sponsor.

NCT NCT02293941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02293941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests in HCV Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies Either Alone or in Combination With Ribavirin
Lead sponsor
TaiwanJ Pharmaceuticals Co., Ltd
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2014
Completion date
August 30, 2017
Enrollment
54 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c